← Leaderboards
Joshua Aiden Hill
Fred Hutchinson Cancer Center
$6,198,358
Attributed
$7,581,437
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.6M · FY2015–25$2M$1.5M$1M$500K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,581,437 · 4
By mechanism
U01$3,686,913 · 1
R01$2,766,158 · 1
K23$922,465 · 1
K24$205,901 · 1
Top collaborators
- Miguel-Angel Perales3 shared
Most similar at Fred Hutchinson Cancer Center
Same institution · by research overlap
- Jesse D Bloom$13,760,302
- Matthew Adam Triplette$3,477,875
- Marie Bleakley$9,428,742
- William Samuel Nutt$88,872
Others in their field
Top investigators on “Infection”
- Wafaa M. El-Sadr · Columbia University Health Sciences$965,939,185
- Lawrence Corey · Fred Hutchinson Cancer Center$789,608,171
- Judith S. Currier · University Of California Los Angeles$511,038,212
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$463,711,983
- Richard Marlink · Elizabeth Glaser Pediatric Aids Fdn$457,210,249
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$415,229,497
Research focus
InfectionPathogenCommunicable DiseasesCellsEnsureBloodAffectInnovationProgramsSamplingLaboratoriesHumoral ImmunitiesMedicineCharacteristicsAdultEpidemiologyInfection PreventionBlood TestsCytokine Release SyndromeImmunoglobulinsAntibodiesKineticsCar T Cell TherapyCd19 Gene
Grant awards (15)
Immunoglobulin Replacement Therapy and Infectious Complications After CD19-Targeted CAR-T-Cell Therapy$977,273
R01 · FY2025 · CA · contact PI
Infection prevention strategies after CAR-T cell therapy$205,901
K24 · FY2025 · AI · contact PI
Immunoglobulin Replacement Therapy and Infectious Complications After CD19-Targeted CAR-T-Cell Therapy$858,502
R01 · FY2024 · CA · contact PI
Humoral immunity after CAR-T cell therapy for B cell malignancies: The HICAR Study$624,921
U01 · FY2024 · CA · contact PI
Immunoglobulin Replacement Therapy and Infectious Complications After CD19-Targeted CAR-T-Cell Therapy$930,383
R01 · FY2023 · CA · contact PI
Humoral immunity after CAR-T cell therapy for B cell malignancies: The HICAR Study$644,646
U01 · FY2023 · CA · contact PI
Humoral immunity after CAR-T cell therapy for B cell malignancies: The HICAR Study$908,642
U01 · FY2022 · CA · contact PI
Humoral immunity after CAR-T cell therapy for B cell malignancies: The HICAR Study$662,560
U01 · FY2021 · CA · contact PI
Humoral immunity after CAR-T cell therapy for B cell malignancies: The HICAR Study$670,697
U01 · FY2020 · CA · contact PI
Humoral immunity after CAR-T cell therapy for B cell malignancies: The HICAR Study$175,447
U01 · FY2020 · CA · contact PI
Human Herpesvirus 6 in Lower Respiratory Tract Disease and Chromosomal Integration after Hematopoietic Cell Transplantation$190,557
K23 · FY2019 · AI · contact PI
Human Herpesvirus 6 in Lower Respiratory Tract Disease and Chromosomal Integration after Hematopoietic Cell Transplantation$190,557
K23 · FY2018 · AI · contact PI
Human Herpesvirus 6 in Lower Respiratory Tract Disease and Chromosomal Integration after Hematopoietic Cell Transplantation$190,557
K23 · FY2017 · AI · contact PI
Human Herpesvirus 6 in Lower Respiratory Tract Disease and Chromosomal Integration after Hematopoietic Cell Transplantation$174,397
K23 · FY2016 · AI · contact PI
Human Herpesvirus 6 in Lower Respiratory Tract Disease and Chromosomal Integration after Hematopoietic Cell Transplantation$176,397
K23 · FY2015 · AI · contact PI